|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/23/21 Rubius Therapeutics, Inc. 10-K 12/31/20 82:12M Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.86M
2: EX-21.1 Subsidiaries List HTML 23K
3: EX-23.1 Consent of Expert or Counsel HTML 23K
4: EX-31.1 Certification -- §302 - SOA'02 HTML 28K
5: EX-31.2 Certification -- §302 - SOA'02 HTML 28K
6: EX-32.1 Certification -- §906 - SOA'02 HTML 24K
7: EX-32.2 Certification -- §906 - SOA'02 HTML 24K
14: R1 Document and Entity Information HTML 88K
15: R2 Consolidated Balance Sheets HTML 101K
16: R3 Consolidated Balance Sheets (Parenthetical) HTML 40K
17: R4 Consolidated Statements of Operations and HTML 70K
Comprehensive Loss
18: R5 Consolidated Statements of Operations and HTML 26K
Comprehensive Loss (Parenthetical)
19: R6 Consolidated Statements of Convertible Preferred HTML 105K
Stock and Stockholders' Equity (Deficit)
20: R7 Consolidated Statements of Convertible Preferred HTML 25K
Stock and Stockholders' Equity (Deficit)
(Parenthetical)
21: R8 Consolidated Statements of Cash Flows HTML 131K
22: R9 Nature of the Business and Basis of Presentation HTML 32K
23: R10 Summary of Significant Accounting Policies HTML 119K
24: R11 Investments and Fair Value of Financial Assets and HTML 120K
Liabilities
25: R12 Property, Plant and Equipment, Net HTML 64K
26: R13 Debt HTML 52K
27: R14 Convertible Preferred Stock HTML 27K
28: R15 Warrants to Purchase Convertible Preferred Stock HTML 26K
29: R16 Equity HTML 29K
30: R17 Stock-Based Compensation HTML 139K
31: R18 Income Taxes HTML 94K
32: R19 Commitments and Contingencies HTML 30K
33: R20 Leases HTML 81K
34: R21 Net Loss Per Share HTML 56K
35: R22 Related Parties HTML 29K
36: R23 Selected Quarterly Financial Data (Unaudited) HTML 79K
37: R24 Summary of Significant Accounting Policies HTML 170K
(Policies)
38: R25 Summary of Significant Accounting Policies HTML 87K
(Tables)
39: R26 Investments and Fair Value of Financial Assets and HTML 121K
Liabilities (Tables)
40: R27 Property, Plant and Equipment, Net (Tables) HTML 47K
41: R28 Accrued Expenses and Other Current Liabilities HTML 38K
(Tables)
42: R29 Debt (Tables) HTML 49K
43: R30 Stock-Based Compensation (Tables) HTML 130K
44: R31 Income Taxes (Tables) HTML 91K
45: R32 Leases (Tables) HTML 76K
46: R33 Net Loss Per Share (Tables) HTML 57K
47: R34 Selected Quarterly Financial Data (Unaudited) HTML 79K
(Tables)
48: R35 Nature of the Business and Basis of Presentation HTML 58K
(Details)
49: R36 Summary of Significant Accounting Policies HTML 39K
(Details)
50: R37 Summary of Significant Accounting Policies - HTML 37K
Estimated useful life (Details)
51: R38 Summary of Significant Accounting Policies - HTML 113K
Recently Adopted Accounting Pronouncements
(Details)
52: R39 Investments and Fair Value of Financial Assets and HTML 73K
Liabilities (Details)
53: R40 Property, Plant and Equipment, Net (Details) HTML 65K
54: R41 Accrued Expenses and Other Current Liabilities HTML 36K
(Details)
55: R42 Debt (Details) HTML 82K
56: R43 Debt - Current and Non current (Details) HTML 35K
57: R44 Convertible Preferred Stock (Details) HTML 56K
58: R45 Warrants to Purchase Convertible Preferred Stock HTML 45K
(Details)
59: R46 Equity (Details) HTML 62K
60: R47 Stock-Based Compensation (Details) HTML 55K
61: R48 Stock-Based Compensation - Employees, directors HTML 31K
and non-employees (Details)
62: R49 Stock-Based Compensation - Option activity HTML 85K
(Details)
63: R50 Stock-Based Compensation - Performance based stock HTML 84K
options (Details)
64: R51 Stock-Based Compensation - Restricted Common Stock HTML 87K
(Details)
65: R52 Stock-Based Compensation - Compensation expense HTML 64K
(Details)
66: R53 Income Taxes (Details) HTML 48K
67: R54 Income Taxes - U S federal statutory income tax HTML 42K
rate (Details)
68: R55 Income Taxes - Net deferred tax assets (Details) HTML 53K
69: R56 Income Taxes - Valuation allowance for deferred HTML 27K
tax assets (Details)
70: R57 Commitments and Contingencies - Collaborative HTML 31K
Arrangements and Non-collaborative Arrangement
(Details)
71: R58 Commitments and Contingencies - Defined HTML 31K
Contribution Plan (Details)
72: R59 Leases (Details) HTML 57K
73: R60 Leases - Minimum lease payments (Details) HTML 42K
74: R61 Leases - Lease Portfolio (Details) HTML 47K
75: R62 Net Loss Per Share - Weighted Average Shares HTML 39K
(Details)
76: R63 Net Loss Per Share - Antidilutive Securities HTML 35K
(Details)
77: R64 Related Parties (Details) HTML 66K
78: R65 Selected Quarterly Financial Data (Unaudited) HTML 41K
(Details)
80: XML IDEA XML File -- Filing Summary XML 150K
13: XML XBRL Instance -- ruby-20201231x10k_htm XML 2.26M
79: EXCEL IDEA Workbook of Financial Reports XLSX 114K
9: EX-101.CAL XBRL Calculations -- ruby-20201231_cal XML 175K
10: EX-101.DEF XBRL Definitions -- ruby-20201231_def XML 641K
11: EX-101.LAB XBRL Labels -- ruby-20201231_lab XML 1.50M
12: EX-101.PRE XBRL Presentations -- ruby-20201231_pre XML 1.12M
8: EX-101.SCH XBRL Schema -- ruby-20201231 XSD 179K
81: JSON XBRL Instance as JSON Data -- MetaLinks 398± 605K
82: ZIP XBRL Zipped Folder -- 0001558370-21-001412-xbrl Zip 937K
Exhibit 21.1
Subsidiary |
| Jurisdiction of Incorporation |
Rubius Therapeutics Securities Corporation | Massachusetts |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/18/21 Rubius Therapeutics, Inc. 8-K:1,9 3/16/21 12:582K Toppan Merrill/FA 3/18/21 Rubius Therapeutics, Inc. 424B5 1:772K Toppan Merrill/FA 3/15/21 Rubius Therapeutics, Inc. 424B5 1:774K Toppan Merrill/FA |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 9/28/20 Rubius Therapeutics, Inc. 8-K:5,9 9/23/20 12:359K Toppan Merrill/FA 8/10/20 Rubius Therapeutics, Inc. 10-Q 6/30/20 53:5.3M Toppan Merrill Bridge/FA 5/11/20 Rubius Therapeutics, Inc. 10-Q 3/31/20 53:5M Toppan Merrill Bridge/FA 3/12/20 Rubius Therapeutics, Inc. 10-K 12/31/19 86:13M Toppan Merrill Bridge/FA 11/14/19 Rubius Therapeutics, Inc. 10-Q 9/30/19 67:7.4M Toppan Merrill Bridge/FA 8/01/19 Rubius Therapeutics, Inc. S-3 7:1.7M Toppan Merrill-FA 5/15/19 Rubius Therapeutics, Inc. 10-K/A 12/31/18 5:313K Toppan Merrill Bridge/FA 7/23/18 Rubius Therapeutics, Inc. 8-K:5,8,9 7/17/18 3:223K Toppan Merrill/FA 7/09/18 Rubius Therapeutics, Inc. S-1/A 10:5.6M Toppan Merrill-FA 7/02/18 Rubius Therapeutics, Inc. S-1/A 7:1M Toppan Merrill-FA 6/22/18 Rubius Therapeutics, Inc. S-1 18:11M Toppan Merrill-FA |